Barclays
LEXX icon

Barclays’s Lexaria Bioscience LEXX Stock Holding History

Barclays’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52 Buy
+6
New +$65 ﹤0.01% 5234

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's LEXX Position: Q2 2026 in Review

Barclays opened a new position in Lexaria Bioscience (LEXX) in Q2 2026: 6 shares worth $52. The stake represents ﹤0.01% of the portfolio and ranks #5234 among its holdings.

29 funds tracked by Wall St. Rank hold LEXX as of Q2 2026.

  • Barclays held 6 shares of Lexaria Bioscience worth $52 as of Q2 2026.
  • Lexaria Bioscience was a new Barclays position in Q2 2026.
  • Lexaria Bioscience made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5234 holding.
  • 29 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.